News

Filter

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Impax and Tolmar enter generic drug distribution deal

27-06-2012

US generic drugmaker Impax Laboratories (Nasdaq: IPXL) has entered into a collaboration with contract…

GenericsImpax LaboratoriesLicensingMarkets & MarketingResearchTolmar

Impax buys US rights to Zomig

01-02-2012

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories (Nasdaq: IPXL) has licensed…

AstraZenecaImpax LaboratoriesLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalZomig

GlaxoSmithKline in $186 million deal with Impax for Ph III Parkinson’s drug

17-12-2010

UK drugs giant GlaxoSmithKline (LSE: GSK) and Impax Pharmaceuticals, the brand products division of USA-based…

GlaxoSmithKlineImpax LaboratoriesLicensingNeurologicalPharmaceutical

Impax now to co-promote Pfizer’s Lyrica; updates on APEX-PD trial; Pfizer in deal with Stemgent on reagents

16-04-2010

Impax Pharmaceuticals, the brand products division of Impax Laboratories, has amended its 2008 co-promotion…

Impax LaboratoriesLicensingLyricaNeurologicalPfizerPharmaceuticalPristiqResearch

COMPANY SPOTLIGHT

Menarini

Back to top